Multidrug resistance protein 2 genetic polymorphism and colorectal cancer recurrence in patients receiving adjuvant FOLFOX-4 chemotherapy.
about
Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane VesiclesDrug resistance reversed by silencing LIM domain-containing protein 1 expression in colorectal carcinoma.Genetic variants as potential predictive biomarkers in advanced colorectal cancer patients treated with oxaliplatin-based chemotherapy.Over-activation of AKT signaling leading to 5-Fluorouracil resistance in SNU-C5/5-FU cells.miR-34a Regulates Multidrug Resistance via Positively Modulating OAZ2 Signaling in Colon Cancer Cells
P2860
Multidrug resistance protein 2 genetic polymorphism and colorectal cancer recurrence in patients receiving adjuvant FOLFOX-4 chemotherapy.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Multidrug resistance protein 2 ...... djuvant FOLFOX-4 chemotherapy.
@en
Multidrug resistance protein 2 ...... djuvant FOLFOX-4 chemotherapy.
@nl
type
label
Multidrug resistance protein 2 ...... djuvant FOLFOX-4 chemotherapy.
@en
Multidrug resistance protein 2 ...... djuvant FOLFOX-4 chemotherapy.
@nl
prefLabel
Multidrug resistance protein 2 ...... djuvant FOLFOX-4 chemotherapy.
@en
Multidrug resistance protein 2 ...... djuvant FOLFOX-4 chemotherapy.
@nl
P2093
P356
P1476
Multidrug resistance protein 2 ...... djuvant FOLFOX-4 chemotherapy.
@en
P2093
Ahad Khoshzaban
Masoud Vakili
Mojgan Mirakhorli
Reza Rozafzon
Sabariah Abdul Rahman
Syahrilnizam Abdullah
P304
P356
10.3892/MMR.2012.1226
P577
2012-12-07T00:00:00Z